Literature DB >> 30597203

Effectiveness of Opioids for Chronic Noncancer Pain: A Two-Year Multicenter, Prospective Cohort Study With Propensity Score Matching.

Dalila R Veiga1, Matilde Monteiro-Soares2, Liliane Mendonça3, Rute Sampaio4, José M Castro-Lopes5, Luís F Azevedo6.   

Abstract

Opioid use in chronic non cancer pain (CNCP) is still controversial regarding their effectiveness and safety. We conducted a 2-year prospective cohort study in 4 multidisciplinary chronic pain clinics to assess long-term opioid effectiveness in CNCP patients. All adult CNCP patients consecutively admitted to their first consultation were recruited. Demographic and clinical data were collected, and propensity score matching was used to adjust for differences between opioid users and nonusers. The Brief Pain Inventory and the Short version of Treatment Outcomes in Pain Survey were used to measure pain outcomes and quality of life. A total of 529 subjects were matched and included in our analysis. Rate of prescription opioid use was 59.7% at baseline, which increased to 70.3% over 2 years, of which 42.7% of the prescriptions were for strong opioids. Opioid users reported no improvement regarding pain symptoms, physical function, emotional function, and social/familiar disability. Opioid users reported higher satisfaction with care and outcomes at 1 year of follow-up, but at 2 years, they only reported improvement in satisfaction with outcomes. Opioids have shown limited effectiveness in long-term CNCP management, as opioid users presented no improvements regarding functional outcomes and quality of life. These findings emphasize the need for proper selection and outcome assessment of CNCP patients prescribed opioids. PERSPECTIVE: This study adds important additional evidence concerning the controversial use of opioids in CNCP management. Opioid users presented no improvement regarding pain relief, functional outcomes and quality of life over 2 years of follow-up. Therefore, our results support and highlight the limited effectiveness of opioids in long-term CNCP management.
Copyright © 2018 the American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioids; chronic noncancer pain; effectiveness; propensity score; quality of life

Year:  2018        PMID: 30597203     DOI: 10.1016/j.jpain.2018.12.007

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  5 in total

1.  Incident Functional Limitations Among Community-Dwelling Adults Using Opioids: A Retrospective Cohort Study Using a Propensity Analysis with the Health and Retirement Study.

Authors:  Kevin T Pritchard; Brian Downer; Mukaila A Raji; Jacques Baillargeon; Yong-Fang Kuo
Journal:  Drugs Aging       Date:  2022-06-17       Impact factor: 4.271

2.  Home-Based EEG Neurofeedback Intervention for the Management of Chronic Pain.

Authors:  Nick Birch; Jon Graham; Christine Ozolins; Kaushalya Kumarasinghe; Faisal Almesfer
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-27

3.  Prevalence of Long-Term Opioid Therapy in a Chronic Non-Cancer Pain Population Attending a University-Based Tertiary Pain Clinic in Sweden: A Cross-Sectional Study.

Authors:  Henrik Grelz; Marcelo Rivano Fischer; Mirnabi Priouzifard; Patrik Midlöv; Åsa Ringqvist
Journal:  J Rehabil Med       Date:  2022-04-29       Impact factor: 3.959

4.  Satisfaction and effectiveness of opioid pain management among adults with cystic fibrosis: A mixed methods study.

Authors:  Sarah Allgood; Jessica L Zemlak; Elisabeth Dellon; Siddhartha G Kapnadak; Jessica Goggin; Noah Lechtzin
Journal:  J Cyst Fibros       Date:  2021-07-10       Impact factor: 5.482

5.  Opioid Pain Medication Prescription for Chronic Pain in Primary Care Centers: The Roles of Pain Acceptance, Pain Intensity, Depressive Symptoms, Pain Catastrophizing, Sex, and Age.

Authors:  Carmen Ramírez-Maestre; Ángela Reyes-Pérez; Rosa Esteve; Alicia E López-Martínez; Sonia Bernardes; Mark P Jensen
Journal:  Int J Environ Res Public Health       Date:  2020-09-03       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.